

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 24, 2020 (the “**C**”) issued by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**C**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**H**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to sell, acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**U.S. S**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(**深圳市海普瑞藥業集團股份有限公司**)

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(**Stock Code: 9989**)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on July 30, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of the stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C., the Stabilization Manager, its affiliates or any person acting for it during the stabilization period is set out in this announcement.

LAPSE OF THE OVER-ALLOTMENT OPTION

The Joint Global Coordinators, on behalf of the International Underwriters, did not exercise the Over-allotment Option during the stabilization period, and the Over-allotment Option lapsed on July 30, 2020.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on July 30, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C., the Stabilization Manager, its affiliates or any person acting for it during the stabilization period are set out below:

- (i) over-allocation of an aggregate of 33,014,000 H Shares in the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and
- (ii) the successive purchases of an aggregate of 33,014,000 H Shares at the price range of HK\$15.00 to HK\$18.40 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). The last purchase made by the Stabilization Manager on the market during the stabilization period was on July 30, 2020 at the price of HK\$16.44 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

LAPSE OF THE OVER-ALLOTMENT OPTION

The Joint Global Coordinators, on behalf of the International Underwriters, did not exercise the Over-allotment Option during the stabilization period, and the Over-allotment Option lapsed on July 30, 2020.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company will continue to comply with the public float requirements under Rule 8.08(1)(b) of the Listing Rules.

On behalf of the Board of Directors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li LI
Chairman

Hong Kong, Friday, July 31, 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Li, Ms. Li Tan, Mr. Shan Yu, Mr. Sun Xuan and Mr. Bu Haihua as executive Directors; and Dr. Lu Chuan, Mr. Chen Junfa, and Mr. Wang Zhaohui as independent non-executive Directors.